Advertisement
Advertisement
U.S. Markets close in 42 mins
Advertisement
Advertisement
Advertisement
Advertisement

Immutep Limited (IMMP)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.3200-0.1100 (-3.21%)
As of 03:16PM EST. Market open.
Advertisement
Full screen
Loading interactive chart...
  • GlobeNewswire

    Immutep Successfully Completes Recruitment for Phase II TACTI-002 Study of LAG-3 Therapy, Eftilagimod Alpha

    Enrolled and dosed last patient in the expansion stage of Part A (1st line non-small cell lung cancer (NSCLC)) needed to complete recruitment into all cohorts of the TACTI-002 studyInterim data from Part C (2nd line head & neck squamous cell carcinoma (HNSCC) patients) presented at SITC 2021Additional data from TACTI-002 expected to be reported in H1 calendar year 2022 SYDNEY, AUSTRALIA, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a bi

  • GlobeNewswire

    Immutep Granted Chinese Patent for Eftilagimod Alpha, a Soluble Lag-3 Fusion Protein, in Combination with a PD-1 Pathway Inhibitor

    SYDNEY, AUSTRALIA, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of a new patent (number ZL 201680005401.3) entitled “Combined Preparations for the Treatment of Cancer or Infection” by the Chinese Patent Office. This new Chinese patent follows the grant of the corresponding European and Unite

  • GlobeNewswire

    Immutep Publishes AIPAC, TACTI-002 and TACTI-003 Trial Posters at SITC with Positive New Data for LAG-3 Therapy, Eftilagimod Alpha

    AIPAC poster presentation includes new data and graphs showing: Very encouraging Overall Survival (OS) data from the abstract published on 9 November 2021, including statistically significant benefit in 3 patient subgroups representing a majority of patientsA statistically significant Quality of Life preservation in first 6 months in the eftilagimod alpha (“efti”) group in total populationThe statistically significant increase in peripheral CD8 T cells in patients in the efti group of the total

Advertisement
Advertisement